Lavrov calls on Europe to work harder towards Minsk deal implementationRussian Politics & Diplomacy March 27, 12:07
Italian top diplomat urges to restore dialog between Russian and EUWorld March 27, 12:01
Eurovision scrambles to ensure Russia’s participation in Kiev-hosted song contestSociety & Culture March 27, 11:41
Siberian ex-cop turned sadistic ‘werewolf’ serial killer charged with another 60 murdersSociety & Culture March 27, 11:25
NATO-Russia Council meeting on the horizon – diplomatRussian Politics & Diplomacy March 27, 11:06
Russia’s FSB detains gunmakers, seizes three aircraft gunsRussian Politics & Diplomacy March 27, 10:32
Russian, Tajik troops hold joint anti-terror drills in AsiaMilitary & Defense March 27, 9:11
US calls for release of detained participants in unsanctioned rallies across RussiaWorld March 27, 6:37
Russia conducts six humanitarian operations in Syria in 24 hoursSociety & Culture March 27, 6:34
NOVOSIBIRSK, November 14 (Itar-Tass) - Scientists at Russia's SibEnzyme enterprise in the Siberian city of Novosibirsk have developed a brand new method to diagnose oncological diseases at very early stages, the company’s chief executive, Yevgeny Dubinin, told Itar-Tass at the international forum for technological development Technoprom.
The new method allows to detect cancer cells even if the sample under scrutiny (blood, phlegm, urine or smear) contains only few DNA molecules with abnormally methylated (abnormally working, ‘silent’ genes), according to Dubinin.
The company’s enzyme, whose patented technology detects methylated genes, is used as a tumor marker. Analysis is simple and reliable - carried out on standard equipment, in one vial and in three stages, it takes only about four hours.
“There is almost no early cancer diagnostic in Russia, while treating the disease when it is detected at the third and fourth stages yields little effect,” Dubinin said.
The new method will be indispensable for oncological centres, diagnostic laboratories, and other medical institutions, the director added. The estimated market volume is about 5.5 million examinations and 1.8 million for rare types of cancer.